March 2015
-
Press release
Novartis to present new late-breaking CosentyxTM data at AAD 2015 showing significant patient benefit in achieving clear skinDetailed results from the CLEAR study will be revealed showing Cosentyx superiority to Stelara® in clearing skin (PASI 90 and PASI 100)[1] New data from the long-term Phase III program to…
-
Story From Our Labs
Vision hackerFrom Our Labs -
Story Discovery
Let there be sightDiscovery -
Press release
FDA approves first biosimilar ZarxioTM (filgrastim-sndz) from SandozSandoz is the first company to receive approval of a biosimilar in the US through the new FDA biosimilars pathway established under BPCIA Zarxio is approved for all indications included in the…
-
Press release
Novartis announces completion of transactions with GSKCompletes transactions with GSK including: acquisition of GSK oncology portfolio, creation of Consumer Healthcare joint venture, and sale of non-influenza Vaccines business Sharpens company focus…
-
Press release
Novartis gibt Abschluss von Transaktionen mit GSK bekanntMit GSK abgeschlossene Transaktionen: Übernahme des Onkologie-Portfolios von GSK, Schaffung eines Joint Venture für Consumer Healthcare und Veräusserung des Bereichs Vaccines (ohne Grippeimpfstoffe…
-
Press release
Novartis annonce la conclusion des transactions avec GSKConclusion des transactions avec GSK incluant : l'acquisition du portefeuille oncologie de GSK, la création d'une coentreprise de Consumer Healthcare et la cession de l'activité vaccins (hors…
February 2015
-
Press release
Positive phase II data highlights benefits of Alcon's RTH258 for patients with neovascular (wet) age-related macular degenerationPhase II study met primary endpoint, demonstrating promising visual acuity gains in patients with neovascular (wet) age-related macular degeneration Data shows the potential for less…
-
Press release
Novartis shareholders approve all resolutions proposed by Novartis Board of DirectorsShareholders approve 18th consecutive dividend increase to CHF 2.60 (+6%) per share for 2014 Dr. Joerg Reinhardt confirmed by shareholders as Chairman of the Novartis Board of Directors as well…
-
Press release
Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d'administrationLes actionnaires approuvent la 18e hausse consécutive du dividende, à CHF 2,60 par action (+6 %) au titre de l'exercice 2014. De même que d'autres administrateurs qui étaient candidats à leur…
-
Press release
Aktionäre genehmigen alle Anträge des Verwaltungsrats von NovartisAktionäre genehmigen für 2014 die 18. Dividendenerhöhung in Folge auf CHF 2,60 pro Aktie (+6%) Dr. Jörg Reinhardt als Präsident des Novartis Verwaltungsrats sowie alle weiteren Mitglieder des…
-
Press release
Novartis lung cancer drug Zykadia® recommended for EU approval in patients with ALK+ NSCLC previously treated with crizotinibIf approved, Zykadia (ceritinib) would be the first treatment option for patients in Europe with ALK+ NSCLC previously treated with crizotinib ALK+ NSCLC is driven by a rearrangement of the…
Pagination
- ‹ Previous page
- 1
- …
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- …
- 160
- › Next page